CLYYF (Celyad Oncology) Short Percentage of Float


CLYYF Celyad Oncology SA CLYYF
28 GF Score
Price $0.25
GF Value $0.15
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Celyad Oncology Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CLYYF vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Celyad Oncology's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celyad Oncology Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celyad Oncology's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Celyad Oncology's Short Percentage of Float falls into.


CLYYF
28GF Score
Celyad Oncology SA CLYYF
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Celyad Oncology (CLYYF) Overvalued in 2026?

Based on GuruFocus' analysis, Celyad Oncology stock appears to be overvalued. The current stock price of $0.25 is trading 66.7% above its estimated GF Value™ of $0.15. GuruFocus considers Celyad Oncology to be Significantly Overvalued.

Key valuation signals for CLYYF:

  • Short Percentage of Float:
  • GF Value™: $0.15 vs. price of $0.25 (66.7% above fair value)
  • GF Score™: 28/100 with 6 warning signs

No single metric tells the full story. See the CLYYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celyad Oncology Business Description

Address Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
28GF Score

Get the complete analysis for CLYYF

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price
$0.15
GF Value